Vantia Therapeutics, a British pharmaceutical company, has begun a Phase 2b trial of its lead development compound VA106483 for nocturia, according to a company statement.
The trial is a randomized, double-blind, placebo-controlled study that is expected to recruit about 120 male patients at 20 centers in the United States. The study’s primary end point is the number of nocturnal voids per night. Secondary end points include quality of life and sleep duration.
The medication exerts direct effects on the kidney by binding to vasopressin receptors, which regulate water excretion.
Last June, the company announced positive results from its Phase 2a trial, which showed that oral VA106483 produced a predictable antidiuretic effect in elderly subjects and was generally well tolerated.